Bexxar (Tositumomab and Iodine 1131 Tositumomab) Drug Information: Medication Guide and Patient Information

Pill Identifier Search

May 25, 2012

Bexxar

Non-Hodgkin's Lymphoma »

Non-Hodgkin's lymphoma facts

NHL is a cancer that originates in the lymphatic system.
About 66,000 patients are diagnosed yearly, and approximately 18,000 patients die of NHL yearly in the U.S.
There are several subtypes of NHL, each requiring different treatments.
Symptoms include swollen lymph nodes, weight loss, fever, and night sweats.
NHL is staged on a 1-4 scale with A (no associated symptoms like fever, weight loss, or night sweats) and B subtypes.
Staging the cancer is important to determine treatment and predict the outcome of treatment.
Depending on the stage and type of NHL, treatment can include chemotherapy, biological therapy, stem cell transplant, and/or radiation therapy.

What is non-Hodgkin's lymphoma?

Non-Hodgkin's lymphoma is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most common cancer in the Unite...

Read the Non-Hodgkin's Lymphoma article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Bexxar

Breast Cancer Slideshow Pictures

Pancreatic Cancer Slideshow Pictures

Skin Cancer Slideshow Pictures

font size

PATIENT INFORMATION

Advise patients

To take premedications, including thyroid-blocking agents as prescribed [see WARNINGS AND PRECAUTIONS].
To contact a healthcare professional if they experience signs and symptoms of allergic reactions [see WARNINGS AND PRECAUTIONS].
To report to a health care professional any signs of cytopenias (bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatigue, or symptoms of infection such as fever) [see WARNINGS AND PRECAUTIONS].
Of the need for frequent monitoring for up to 3 months after treatment, and the potential for persistent cytopenias beyond 3 months.
Concerning the risk of radiation exposure to household contacts, pregnant women and small children from radioactive materials remaining in the patient's body following the BEXXAR therapeutic regimen. Provide patient-specific advice orally and in writing [see WARNINGS AND PRECAUTIONS].
Of the need for life-long monitoring for hypothyroidism [see WARNINGS AND PRECAUTIONS].
Who are pregnant that the BEXXAR therapeutic regimen can cause hypothyroidism in the infant [see WARNINGS AND PRECAUTIONS, Use in Special Populations].
To check with their physicians before receiving live virus vaccinations [see WARNINGS AND PRECAUTIONS].
Who are of reproductive potential to use effective contraceptive methods during treatment and for a minimum of 12 months following the BEXXAR therapeutic regimen [see Use in Special Population].
To discontinue nursing during and after the BEXXAR therapeutic regimen [see Use in Special Populations].